Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Acumen PharmaceuticalsABOS +0.53%34 Price-to-Tangible-Book is 3.60 as of Sep. 11, 2026. GuruFocus rates ABOS with a GF Score™ of 34/100. The stock has 3 warning signs investors should review. Among 1,127 Biotechnology companies, Acumen Pharmaceuticals ranks worse than 53.77% on this metric.
Some businesses have very light assets, such as software companies or insurance agencies. The Price-to-Book Ratio does not work well for these companies. Some companies even have negative equity, so the Price-to-Book Ratio cannot be applied to them.
Acumen Pharmaceuticals Price-to-Tangible-Book Related Terms
Acumen Pharmaceuticals Price-to-Tangible-Book Historical Data
* Premium members only.
The historical data trend for Acumen Pharmaceuticals's Price-to-Tangible-Book can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ABOS vs ANTX, IMUX, CRBP: Price-to-Tangible-Book Comparison
For the Biotechnology subindustry, Acumen Pharmaceuticals's Price-to-Tangible-Book, along with its competitors' market caps and Price-to-Tangible-Book data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Acumen Pharmaceuticals Price-to-Tangible-Book vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Acumen Pharmaceuticals's Price-to-Tangible-Book distribution charts can be found below:
* The bar in red indicates where Acumen Pharmaceuticals's Price-to-Tangible-Book falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
A closely related ratio is called PB Ratio. The difference between Price-to-Tangible-Book Ratio and PB Ratio is that book value other than intangibles are used in the calculation.
Acumen Pharmaceuticals (ABOS) has a Price-to-Tangible-Book of 3.60 as of Sep. 11, 2026. Price-to-tangible-book ratio is the ratio of share price to a company's tangible book value per share. View historical data on Acumen Pharmaceuticals and its competitors. According to the industry distribution chart, Acumen Pharmaceuticals ranks #606 out of 1127 companies in the Biotechnology industry, placing it in the top 53.8%.
Is Acumen Pharmaceuticals' Price-to-Tangible-Book too high?
Acumen Pharmaceuticals' current Price-to-Tangible-Book is 3.60. The Biotechnology industry median Price-to-Tangible-Book is 3.27. Acumen Pharmaceuticals' value of 3.60 is 10.1% above this industry median. Based on the distribution chart, Acumen Pharmaceuticals ranks #606 out of 1127 companies in the Biotechnology industry, which is below the industry midpoint. Overall, Acumen Pharmaceuticals has a GF Score™ of 34/100, reflecting its overall financial health beyond just this single metric.
How does Acumen Pharmaceuticals' Price-to-Tangible-Book compare to ANTX and IMUX?
According to the Biotechnology industry distribution chart, Acumen Pharmaceuticals ranks #606 out of 1127 companies for Price-to-Tangible-Book. This places Acumen Pharmaceuticals in the lower half of its industry. The industry median Price-to-Tangible-Book is 3.27. Acumen Pharmaceuticals' value of 3.60 is 10.1% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Price-to-Tangible-Book for a Biotechnology company?
The median Price-to-Tangible-Book among Biotechnology companies is 3.27, based on 1,127 companies in the industry. Companies in the top quartile (top 25%) have a Price-to-Tangible-Book significantly above this median, while those in the bottom quartile fall well below. However, Price-to-Tangible-Book should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Acumen Pharmaceuticals's current Price-to-Tangible-Book of 3.60 is 10.1% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Price-to-Tangible-Book mean?
A high Price-to-Tangible-Book can signal that a stock is expensive relative to its fundamentals. Price-to-tangible-book ratio is the ratio of share price to a company's tangible book value per share. View historical data on Acumen Pharmaceuticals and its competitors. For the Biotechnology industry, the median Price-to-Tangible-Book is 3.27 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Acumen Pharmaceuticals's current Price-to-Tangible-Book is 3.60. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Acumen Pharmaceuticals stock overvalued right now?
Acumen Pharmaceuticals (ABOS) has a current Price-to-Tangible-Book of 3.60. The current Price-to-Tangible-Book is 3.60 and 10.1% above the Biotechnology industry median of 3.27. Acumen Pharmaceuticals' overall GF Score™ is 34/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Price-to-Tangible-Book calculated?
Price-to-Tangible-Book is calculated from a company's financial statements. For Acumen Pharmaceuticals (ABOS), the current Price-to-Tangible-Book is 3.60 as of Sep. 11, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Acumen Pharmaceuticals Inc is a clinical-stage biopharmaceutical company developing a novel disease-modifying approach to target what it believes to be a key underlying cause of Alzheimer's disease. The company's drug candidate, ACU193, is a subclass monoclonal antibody that selectively targets amyloid-beta oligomers. The product pipelines include: ALTITUDE-AD; and INTERCEPT-AD.
34GF Score
Get the complete analysis for ABOS
Price-to-Tangible-Book is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ABOS has been successfully added to your 
